We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best ...

Explore ImmunityBio’s recent market movement, biotech sector trends, and key factors shaping its outlook in a dynamic ...

Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the ...

ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities ...

ImmunityBio Inc.’s shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong ...

Securities fraud class action lawsuit filed -- Class Period: January 19, 2026 through March 24, 2026 -- Deadline to Seek Lead Plaintiff Status: May 26, 2026 -- Key Lawsuit Allegations: Material ...

ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional ...

(NASDAQ: IBRX) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased IBRX securities between January 19, 2026 and March 24, ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

Shiong’s earlier appearance on The Sean Spicer Show as suggesting uses beyond Anktiva’s approved indication. ・Soon-Shiong said the FDA classified the podcast discussion as direct-to-consumer ...